Back to Search

AMANDA SALVADO, MD

MD

Otolaryngology Physician

NPI: 1194988154IndividualAccepts Medicare

Specialties, Licenses & Credentials

Otolaryngology PhysicianPrimary

Otolaryngology

Code: 207Y00000X

A91726(CA)

CMS Specialties

PrimaryOTOLARYNGOLOGY

Education

TULANE UNIVERSITY SCHOOL OF MEDICINE

Class of 2003

Research & Publications (13)

Treatment of complete nasal vestibule stenosis with vestibular stents and mitomycin C.
PMID 18503859·Otolaryngol Head Neck Surg·2008
5-case
Phase II open label trial of imatinib in polycythemia rubra vera.
PMID 19009241·Int J Hematol·2008
3-trial
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
PMID 19248046·Cancer·2009
3-trial
Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis.
PMID 19130059·Rheumatol Int·2009
4-observational
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
PMID 18359865·Neuro Oncol·2008
3-trial
[New argentine consensus of respiratory rehabilitation 2008].
PMID 18786894·Medicina (B Aires)·2008
6-review
[Accuracy of spirometry in the diagnosis of pulmonary restriction].
PMID 18422058·Medicina (B Aires)·2007
8-other
[Lung involvement in systemic sclerosis].
PMID 18051224·Medicina (B Aires)·2007
8-other
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
PMID 17245623·J Neurooncol·2007
3-trial
Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
PMID 16986125·Cancer·2006
8-other
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
PMID 16361636·J Clin Oncol·2005
3-trial
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
PMID 14551133·Blood·2004
3-trial
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
PMID 12767088·Cancer·2003
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3831 HUGHES AVE STE 504
CULVER CITY, CA 90232

Quick Facts

NPI
1194988154
Entity Type
Individual
Gender
Female
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
23
Publications
13

Are you this provider?

Claim Your Profile